NCT02605083View on ClinicalTrials.gov

A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

December 3, 2015

Primary Completion Date

January 11, 2019

Study Completion Date

March 22, 2019

Conditions
Cancer
Interventions
DRUG

eFT508

Will be given orally once or twice daily. Each treatment cycle = 21 days.

Trial Locations (4)

34232

Florida Cancer Specialists, Sarasota

37203

Tennessee Oncology, PLLC, Nashville

77030

MD Anderson Cancer Center, Houston

80218

SCRI at HealthONE, Denver

Sponsors
All Listed Sponsors
lead

Effector Therapeutics

INDUSTRY